What is the recommended treatment for a urinary tract infection (UTI) during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Urinary Tract Infections in Pregnancy

First-line treatment for urinary tract infections during pregnancy should be nitrofurantoin (100 mg twice daily for 5-7 days), fosfomycin trometamol (3g single dose), or cephalosporins, with treatment duration typically 5-7 days depending on the specific medication. 1

Recommended First-Line Antibiotics

  • Nitrofurantoin (100 mg twice daily for 5 days) is effective but should be avoided in the third trimester due to risk of hemolytic anemia in the newborn 1
  • Fosfomycin trometamol (3g single dose) offers convenient administration that improves compliance and is equally effective as multi-day regimens 1
  • Cephalosporins (such as cefixime or cephalexin) are appropriate options, particularly when resistance to other agents is suspected 1, 2
  • For oral therapy of uncomplicated UTIs, cefixime may be particularly rational due to high sensitivity of E. coli, effectiveness, safety, and good compliance in pregnant women 3

Diagnostic Approach

  • A urine culture should always be performed in pregnant women with UTI symptoms before initiating treatment to confirm diagnosis and guide therapy 1, 2
  • All pregnant women should be screened for asymptomatic bacteriuria, as it requires treatment to prevent progression to symptomatic infection 2, 4
  • The presence of Group B streptococci bacteriuria in any concentration during pregnancy requires treatment and intrapartum prophylaxis during labor 2

Treatment Duration and Special Considerations

  • Treatment duration should be 5-7 days for symptomatic UTIs in pregnancy, as shorter courses (1-3 days) are generally not recommended for complete eradication 1
  • For severe infections or pyelonephritis, initial parenteral therapy may be required, with transition to oral therapy after clinical improvement 2
  • Asymptomatic bacteriuria in pregnancy must be treated, as untreated cases can lead to pyelonephritis in up to 40% of cases with subsequent risks to both mother and fetus 5
  • For women with recurrent UTIs during pregnancy, postcoital prophylaxis with a single dose of cephalexin (250 mg) or nitrofurantoin (50 mg) has been shown to be highly effective 6

Antibiotics to Avoid

  • Trimethoprim-sulfamethoxazole should be avoided in the first trimester (potential teratogenic effects) and third trimester (risk of neonatal hyperbilirubinemia) 1, 2
  • Fluoroquinolones are contraindicated throughout pregnancy due to potential adverse effects 1, 2
  • Nitrofurantoin should not be used for suspected pyelonephritis as it doesn't achieve therapeutic concentrations in the bloodstream 2

Common Pitfalls to Avoid

  • Delaying treatment in pregnant women with symptomatic UTI increases risk of pyelonephritis and adverse pregnancy outcomes 2
  • Using unnecessarily long antibiotic courses, which can promote resistance 1
  • Failing to obtain follow-up urine cultures 7 days after treatment to confirm cure 7
  • Neglecting to treat asymptomatic bacteriuria, which can lead to serious maternal and fetal complications 4

References

Guideline

Treatment of Urinary Tract Infections in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of UTI During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Effective prophylaxis for recurrent urinary tract infections during pregnancy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Research

Recommended treatment for urinary tract infection in pregnancy.

The Annals of pharmacotherapy, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.